Lidocaine

Lidoderm relieves postherpetic neuralgia pain on intact skin; ZTlido explicitly labels this use in adults. Pediatric patch safety/effectiveness are unestablished. Selected oral viscous solution anesthetizes irritated/inflamed mouth or pharyngeal mucosa and can reduce gagging during dental impressions/X-rays; it is not a routine teething medicine.

Selected Xylocaine is for clinician-administered local/regional anesthesia, including infiltration, peripheral nerve and specified central neural techniques. Its IV regional block indication is not an IV systemic antiarrhythmic or chronic pain infusion regimen. Other topical/OTC products, dental cartridges, intra-articular infusion and specialist technique protocols are excluded.

2% is 20 mg/mL. Usual healthy-adult dose is 15 mL undiluted, but single-dose maximum is 4.5 mg/kg and never over 300 mg, so lower-weight patients may require less. For mouth use, swish and spit; pharyngeal use is gargled and may be swallowed as prescribed. Doses at least three hours apart; maximum eight doses/24 hours. Shake this selected product well and measure accurately.

Under three: only when safer alternatives are unavailable/failed for an appropriate indication, not routine teething. Accurately apply no more than 1.2 mL to the immediate area with a cotton-tipped applicator; at least three hours apart, maximum four doses in twelve hours, and only if treatment needs no more than 1.2 mL. Above three, dose depends on age/weight/development; label example age five/50 lb is 75–100 mg (3.7–5 mL), not a universal pediatric dose or maximum for every child. The text does not resolve an exact-three-year automatic dose branch; obtain a specific prescription.

For normal healthy adults, without epinephrine: no more than 4.5 mg/kg and generally 300 mg total; with epinephrine: no more than 7 mg/kg and generally 500 mg total. These are ceilings, not target doses; reduced/procedure-specific limits apply. IV regional anesthesia uses no vasoconstrictor and maximum 4 mg/kg adult; pediatric induction maximum 3 mg/kg with appropriately dilute solution. Other pediatric doses are individualized; no adult cap is assigned to children.

Only appropriately preservative-free single-dose forms are recommended for epidural use; preserved solutions are unsuitable for epidural/spinal anesthesia. Selected injection procedure tables and paracervical/continuous-epidural restrictions are not a self-contained procedural manual here. ZTlido permits brief water exposure (shower ten minutes/immersion fifteen), gentle patting dry and moderate exercise; Lidoderm instead advises avoiding water. Never apply external heat directly to either patch.

Selected products contraindicate amide-local-anesthetic hypersensitivity; dermal/viscous labels also expressly include product-component sensitivity. Verify preserved/sulfite formulations separately. Safety restrictions of a product/technique must not be reduced to a generic lidocaine name.

Selected viscous oral topical 2% warns of seizures, cardiopulmonary arrest and death under age three when dose/administration rules were not strictly followed. Generally do not use for teething; other under-three use is restricted to situations with no successful safer alternative. The selected dermal and Xylocaine injection labels do not have this boxed warning; systemic toxicity warnings still apply.

Dermal irritation, burning, redness/pruritus and blistering can occur. Systemic effects include tinnitus, dizziness, drowsiness, tremor, seizures, respiratory depression, bradycardia/hypotension and collapse; allergy/anaphylaxis and methemoglobinemia are reported. Regional techniques can cause additional neurologic injury/blocks. Apparent local use does not exclude systemic toxicity.

Class I antiarrhythmics such as mexiletine can add toxicity. Count absorbed drug from all local-anesthetic formulations, including patches plus procedures. Oxidizing drugs such as nitrates, benzocaine, dapsone and selected other medicines can increase methemoglobinemia risk; review the full source list rather than infer that all co-use is contraindicated.

Epinephrine-containing local solutions with MAOIs or tricyclic antidepressants may cause severe/prolonged hypertension; concurrent therapy generally should be avoided, or closely monitored if necessary. Phenothiazines/butyrophenones can change epinephrine pressor effects; vasopressors plus ergot oxytocics can cause severe hypertension/cerebrovascular events.

Human developmental-risk data for dermal products are limited; animal results do not prove safety. Lidocaine crosses the placenta and obstetric regional techniques require maternal/fetal monitoring. Modern ZTlido labeling and Lidoderm describe milk transfer; older viscous/injection wording says unknown excretion. Retain the source distinction while recognizing verified milk transfer and reviewing maternal need, infant risk and total anesthetic exposure with a clinician.

Selected patch pediatric safety/effectiveness are unestablished. Viscous under-three restrictions/box and age/weight dosing are explicit above; no automatic exact-three branch is established. Injection pediatric doses and techniques require specialist selection. Older/debilitated patients need smaller patch areas or reduced injection/mucosal doses according to condition, not an invented age-only numeric maximum.

Hepatic metabolism is central; severe disease can raise toxic levels and prolong elimination. Renal dysfunction can accumulate metabolites despite less change in parent kinetics. No universal CrCl/Child-Pugh dose table exists across these products; review total exposure, smaller area/lower dose and clinical monitoring.

Lidocaine inhibits ionic flux needed for nerve impulse initiation/conduction. Dermal penetration at labeled patch use provides analgesia below complete sensory blockade; local/regional injection and mucosal anesthesia have different delivery/effect profiles.

Absorption depends on route, area, duration, tissue and epinephrine. Hepatic metabolites include MEGX/GX; urinary excretion predominates and less than 10% is unchanged. IV-derived half-life is about 1.5–2 hours and may lengthen with hepatic disease; this is not a patch-wear schedule. ZTlido 36 mg and Lidoderm 700 mg per unit produce comparable labeled exposure despite different drug loading; do not convert by contents alone.

Confirm route, concentration, units and timing; measure viscous doses with a calibrated device and shake the selected product. Observe injected patients’ circulation, ventilation and consciousness; report tinnitus, confusion, tremor or drowsiness. Seek emergency care for blue/gray skin, seizures, breathing problems or collapse. Follow sixty-minute food restriction after oral anesthesia and avoid chewing while numb. Keep new/used patches and liquids secured; fold patch adhesive inward and dispose safely. Remove for irritation and wait until it resolves before reapplying.

Stop/remove exposure and obtain emergency/Poison Control assistance for suspected toxicity, excess doses or child ingestion. All sources of anesthetic matter. Dialysis has negligible overdose value in dermal labeling. No safe blood/dose threshold, home antidote or complete emergency lipid-rescue/procedural protocol is supplied here.

Dermal

Lidoderm 5% 700 mg/patch · NDC 61959-001-30

Topical system

ZTlido 1.8% 36 mg/system · NDC 69557-111-30

Viscous oral topical

Advagen 2% 20 mg/mL · 100 mL, NDC 72888-125-26

Injection example

Fresenius Xylocaine 1% 10 mg/mL · 20 mL multiple-dose vial, NDC 63323-485-41

Both selected dermal units measure 10 × 14 cm but differ in base/loading. Xylocaine supplied forms include 1%/2% plain, selected MPF single-dose plain forms and 1% with epinephrine 1:100,000; its procedural text describes additional forms not all supplied in this record. MPF means methylparaben-free; multiple-dose preservatives and epinephrine sulfite require attention. These are not oral solution substitutes or IV antiarrhythmic products.

Lidoderm: 25°C, excursions 15–30°C; keep sealed and apply immediately after opening. ZTlido: 20–25°C, excursions 15–30°C; same sealed/immediate-use and safe folded disposal. Selected viscous: 20–25°C, excursions 15–30°C; shake well and secure the bottle. Selected injection: 20–25°C, protect from light; inspect solution/container and follow exact sterile technique/expiry. No universal opened-container/compounded beyond-use date is supplied.